1. Volume 7, Issue 7, Pages 583-590 (July 2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study 
Daniel G Healy, MD, Mario Falchi, PhD, Sean S O'Sullivan, MD, Vincenzo Bonifati, MD, Alexandra Durr, MD, Susan Bressman, MD, Alexis Brice, MD, Jan Aasly, MD, Cyrus P Zabetian, MD, Stefano Goldwurm, PhD, Joaquim J Ferreira, MD, Eduardo Tolosa, MD, Denise M Kay, PhD, Christine Klein, MD, David R Williams, MD, Connie Marras, MD, Anthony E Lang, MD, Zbigniew K Wszolek, MD, Jose Berciano, MD, Anthony HV Schapira, MD, Timothy Lynch, MD, Kailash P Bhatia, MD, Thomas Gasser, MD, Andrew J Lees, MD, Nicholas W Wood, MD 
The Lancet Neurology 
Volume 7, Issue 7, Pages (July 2008)
DOI: /S (08)
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1
Age of PD onset plotted against the cumulative percentage of patients in the PARK2, LRRK2, or QSBB series
QSBB=Queen Square brain bank.
The Lancet Neurology 2008 7, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2
Point prevalence of neuropsychiatric symptoms in patients with mutations in LRRK2 after various durations of the symptoms of PD
The Lancet Neurology 2008 7, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

4. Figure 3 Age-specific risk of PD
Risk is estimated with the Kaplan-Meier method for the whole sample and with the maximum-likelihood estimation (ML) for all patients with mutations in LRRK2 combined.
The Lancet Neurology 2008 7, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions